Stocks
Funds
Screener
Sectors
Watchlists
LIAN

LIAN - LianBio Stock Price, Fair Value and News

$0.12+0.03 (+33.33%)
Market Closed

Price Targets

LIAN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIAN Price Action

LIAN RSI Chart

LIAN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LIAN Valuation

LIAN Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

LIAN Fundamentals

LIAN Earnings

LIAN Profitability

LIAN Investor Care

LIAN
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITElianbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES163

LianBio Frequently Asked Questions


LIAN is the stock ticker symbol of LianBio. Every public company that trades on a stock exchange gets a ticker symbol.